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Abstract 
Background: The cerebrospinal fluid (CSF)/serum quotient of albumin (QAlb) is the most used biomarker for the 
evaluation of blood–cerebrospinal fluid barrier (B-CSF-B) permeability. For years QAlb was considered only as an 
age-related parameter but recently it has also been associated to sex. The aim of the present study was to explore the 
impact of sex in the determination of B-CSF-B dysfunction.
Methods: The analysis was retrospectively conducted on subjects consecutively admitted to the neurological ward. 
CSF and serum albumin levels were measured by immunonephelometry and pathological QAlb thresholds were 
considered: 6.5 under 40 years, 8.0 in the age 40–60 and 9.0 over 60 years.
Results: 1209 subjects were included in the study. 718 females and 491 males (age: 15–88 years): 24.6% of patients 
had a diagnosis of multiple sclerosis, 23.2% suffered from other inflammatory neurological diseases, 24.6% were 
affected by non-inflammatory neurological diseases, and for 27.6% of patients the final neurological diagnosis could 
not be traced. Dysfunctional B-CSF-B was detected more frequently (44 vs. 20.1%, p < 0.0001) and median QAlb value 
were higher (7.18 vs. 4.87, p < 0.0001) in males than in females in the overall study population and in all disease sub-
groups. QAlb and age were positively correlated both in female (p < 0.0001) and male (p < 0.0001) patients, however 
the slopes of the two regression lines were not significantly different (p = 0.7149), while the difference between the 
elevations was extremely significant (p < 0.0001) with a gap of 2.2 units between the two sexes. Finally, in a multivari-
able linear regression analysis increased age and male sex were independently associated with higher QAlb in the 
overall study population (both p < 0.001) and after stratification by age and disease group.
Conclusions: Accordingly, identification and validation of sex-targeted QAlb thresholds should be considered as a 
novel tool in an effort to achieve more precision in the medical approach.
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Background
Brain homeostasis is maintained by means of two differ-
ent barriers: the blood–cerebrospinal fluid (CSF) barrier 
(B-CSF-B) formed by the choroid plexus epithelial cell, 
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and the blood–brain barrier (BBB) formed by the cer-
ebral blood vessel endothelium [1, 2]. Since both barri-
ers are in chemical–physical equilibrium with each other 
and functionally overlap, the term ‘BBB’ is most com-
monly used simply to refer to the entire functional sys-
tem separating blood from CSF and nervous tissue [3]. In 
clinical routine, the CSF/serum quotient of albumin—the 
most concentrated protein in the CSF-, namely QAlb, is 
the most used and reliable biomarker to assess B-CSF-
B permeability [4, 5]. Albumin is produced in the liver 
and is not catabolised within the central nervous system 
(CNS), and it is generally thought that all albumin meas-
ured in CSF is of plasma derivation [6], although there is 
some evidence that glial cells can produce albumin [7].
Within threshold values QAlb indicates a “normal” 
B-CSF-B permeability, while values beyond the thresh-
old reflect B-CSF-B dysfunction [8]. The use of QAlb is 
preferable to the simple measurement of CSF total pro-
teins [9]. An isolated abnormal elevation of QAlb with 
no other CSF pathological sign has been described in 
acute and chronic inflammatory demyelinating polyneu-
ropathy and normal pressure hydrocephalus, but has also 
been seen in patients with no neurological disease [10]. 
QAlb threshold values increase with age [8, 11] indicat-
ing an age-related progressive loss of B-CSF-B integrity 
[12], reduced CSF flow rate [13] and a decreased CSF 
turnover [14]. While the dependence between QAlb and 
age is clear [15], evidence of sex-related differences is less 
explored [16].
QAlb values were recently reported to be higher in 
men than women regardless of age in a large population 
of patients with unspecified disorders and in healthy vol-
unteers [17]. The implication of QAlb sex-related differ-
ences in clinical practice was, however, not addressed.
Owing to sex-related differences in brain development, 
structure, and neurotransmission [18], exploring sexual 
dimorphisms in the brain may be key to understanding 
the role of sex in predisposing to neurological diseases 
[19].
Our aim was to investigate whether sex has an impact 
on B-CSF-B permeability by analysing QAlb in a cohort 
of neurological patients.
Methods
Study design
Clinical and laboratory anonymized data were retrospec-
tively collected from patients hospitalized from 2000 to 
2018 in the ‘S. Anna’ University Hospital (Azienda Ospe-
daliero-Universitaria S. Anna), in Ferrara, northern Italy. 
The study was approved by the local Committee for Med-
ical Ethics in Research, “Comitato Etico di Area Vasta 
Emilia Centro della Regione Emilia-Romagna” (Prot. N. 
770/2018/Oss/AOUFe, dated 12/12/2018) and written 
informed consent was obtained.
Patients and methods
All patients included in the study had undergone lumbar 
puncture for diagnostic purposes. Blood and CSF samples 
had been withdrawn at the same time. CSF and serum 
samples were analysed at room temperature immediately 
after centrifugation or stored in aliquots at − 80 °C until 
assay. All analyses were performed on the 2nd–4th ml of 
CSF after lumbar puncture. For every patient albumin 
levels were measured as part of the diagnostic work-up 
in cell-free CSF and paired serum samples by immuno-
chemical nephelometry with the Beckman Array Pro-
tein System or IMMAGE 800 Immunochemistry System 
(Beckman Instruments, Fullerton, CA, USA) according 
to the procedure of Salden [20]. Albumin quotient was 
calculated to disclose B-CSF-B dysfunction according to 
the formula: QAlb = [Alb]CSF/[Alb]serum × 1000. Nor-
mal QAlb values were considered as < 6.5 for patients 
aged 15–40  years, < 8.0 for patients aged 41–60  years 
and < 9.0 for patients over 60 years [8, 9, 21]. Accordingly, 
QAlb was considered as pathological for values greater 
than or equal to the reported thresholds.
Exclusion criteria were (i) age less than 16 years (ii) lack 
of demographic data (sex and/or age) and (iii) the pres-
ence of xanthochromia and/or high levels of CSF red 
blood cells (> 2000/µl) as suggestive of traumatic lumbar 
puncture or subarachnoid haemorrhage.
These subjects were subsequently diagnosed with mul-
tiple sclerosis (MS), other inflammatory neurological dis-
eases (OIND), including inflammatory diseases of both 
central and peripheral nervous systems, non-inflam-
matory neurological diseases (NIND) and patients with 
untraceable definite neurological diagnosis (UNK). For 
all subjects, sex, age, and QAlb values were collected.
Statistical analysis
Continuous variables with non-normal distribution at 
the Kolmogorov–Smirnov test were reported as median 
(interquartile range, IQR) and comparisons were made 
with Mann–Whitney test. Categorical variables were 
reported as count (percentage) and Chi square test used 
for comparison. Correlations between age and QAlb were 
investigated with Spearman test. In regression analy-
sis F-test was used to compare the fits of linear models. 
Independent predictors of Log-transformed QAlb were 
explored using multivariable linear regression, and age 
and sex were used as reciprocal covariates in the model. 
Two tailed p-values < 0.05 were considered statistically 
significant. The Statistical Package for the Social Sci-
ences  (SPSS®) version 21.0 for Windows, OSX (SPSS Inc., 
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 IBM®, Somers, New York, USA) and  Prism® 8 (GraphPad 
Software Inc.) were used for the statistical analysis.
Results
Patients characteristics
The study was conducted on 1209 individuals, 718 
women and 491 men, aged between 15 and 88 years: 297 
(24.6%) patients had a diagnosis of MS, 281 (23.2%) suf-
fered from OIND, 297 (24.6%) were affected by NIND, 
and for 334 (27.6%) the definite neurological diagnosis 
could not be traced (UNK). The main clinical-demo-
graphic features of the study population are reported in 
Table 1.
The women:men ratio was 1.46:1 in the overall study 
population, 2.19:1 in MS, 0.89:1 in OIND, 0.97:1 in NIND 
and 2.41:1 in UNK group. In the overall study popula-
tion age at admission was higher in men (48.0  years) 
than in women (44.0 years) and in the UNK subgroup it 
was 51.0 years versus 42.4 years, respectively. No further 
significant difference in age distribution was observed 
across groups.
Distribution of the B‑CSF‑B dysfunction in the study 
population grouped by age and diagnosis
In our overall study population, based on QAlb, men 
were reported with a B-CSF-B dysfunction more fre-
quently than women (44.0% vs. 20.1%). After stratifica-
tion by age, 40.8% men vs. 11.8% women under 40 years 
of age were reported with B-CSF-B dysfunction, 44.3% vs. 
23.4% between 41 and 60 years, and 47.1% vs. 33.3% over 
60 years (Table 2). This sex-difference was confirmed in 
all the disease subgroups: 24.7% vs. 7.35% in MS men 
and women, respectively, 59.7% vs. 45.5% in patients with 
OIND, 33.1% vs. 15.8% in NIND and 55.1% vs. 22.0% in 
the UNK group.
Medians of QAlb values in the study population 
and prevalence of sex across QAlb quartiles
Median QAlb values were significantly higher in the 
male than in the female overall study population (7.18 
vs. 4.87), and in all age subgroups: 5.74 vs. 4.19 in the 
under 40  s, 7.33 vs. 5.03 in the group aged between 41 
and 60 years, and 8.87 vs. 6.52 in the over 60 s (Table 3). 
Table 1 Clinical and demographic characteristics of the study population
Age distributions were compared with Mann–Whitney u-test
CNS central nervous system, CSF cerebrospinal fluid, MS multiple sclerosis, NIND non-inflammatory neurological diseases, OIND other inflammatory neurological 
diseases, PNS peripheral nervous system, UNK unknown-neurological diagnosis
Female Male p
All patients, n (%) 718 (59.4) 491 (40.6)
 Age, years: median (IQR) 44 (33–58) 48 (35–65) 0.0002
MS, n (%) 204 (68.7) 93 (31.3)
 Age, years: median (IQR) 37.0 (30.0–45.0) 35.0 (29.0–45.0) 0.5289
 Relapsing–remitting: n 163 72
 Secondary progressive: n 23 11
 Primary progressive: n 18 10
OIND, n (%) 132 (47.0) 149 (53.0)
 Age, years: median (IQR) 52.5 (39.0–63.6) 52.0 (38.5–69.0) 0.5070
 Diagnosis (n) Infectious diseases (17)
Autoimmune neurological diseases (46)
Paraneoplastic CNS neurological syndromes (4)
Aseptic or bacterial meningitis; aseptic encephalitis 
or myelitis (16)
Inflammatory demyelinating neuropathies (40).
Inflammatory neuritis (9)
Infectious diseases (15)
Autoimmune neurological diseases (26)
Paraneoplastic CNS neurological syndromes (10)
Aseptic or bacterial meningitis; aseptic encephalitis 
or myelitis (26)
Inflammatory demyelinating neuropathies (59) 
Inflammatory neuritis (13)
NIND, n (%) 146 (49.2) 151 (50.8)
 Age, years: median (IQR) 52.0 (38.8–68.0) 53.0 (37.0–66.0) 0.7482
 Diagnosis (n) CNS expansions (14)
Vascular diseases (50)
Neurodegenerative diseases (20)
Hereditary/metabolic encephalopathies (4)
Unconsciousness (18)
Non-inflammatory PNS involvement (16)
CSF flow abnormalities (5)
Dementia and Parkinson syndromes (19)
CNS expansions (13)
Vascular diseases (51)
Neurodegenerative diseases (27)
Hereditary/metabolic encephalopathies (2)
Unconsciousness (10)
Non-inflammatory PNS involvement (27)
CSF flow abnormalities (2)
Dementia and Parkinson syndromes (19)
UNK, n (%) 236 (70.7) 98 (29.3)
 Age, years: median (IQR) 42.4 (31.0–58.0) 51.0 (40.8–66.0) 0.0002
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This sex-difference was also found in all the disease sub-
groups: 5.22 vs. 4.10 in MS, 9.22 vs. 6.68 in OIND, 6.34 
vs. 5.09 in NIND and 8.48 vs. 4.89 in UNK (Table 3).
QAlb values were stratified by quartiles (Table  4). 
Prevalence of the female sex was higher in the lower 
quartiles (Chi square test: p < 0.0001) in the overall study 
population and across all disease subgroups (Chi square 
test: MS, p < 0.001; OIND, p = 0.0309; NIND, p = 0.0002; 
UNK, p < 0.0001), also after stratification by age (Chi 
square test: age 16-40 years, p < 0.0001; age 41–60 years, 
p < 0.0001; age > 60 years, p = 0.0071).
Associations between age, sex and QAlb
In the entire study population, QAlb positively corre-
lated with age both in women (r = 0.383, p < 0.0001) and 
in men (r = 0.2578, p < 0.0001) (Fig. 1). The slopes of the 
sex-specific regression lines were not significantly differ-
ent (F = 0.1335, p = 0.7149), while the difference between 
the elevations (1.687 in women vs. 3.903 in men) was 
very significant (F = 37.65, p < 0.0001).In multivariable 
linear regression analysis, both increasing age and sex 
(M) were independently associated with higher QAlb in 
the whole population and in MS, OIND, NIND and UNK 
subgroups (p < 0.001 for all subgroups) (Table 5).
Correlations between age and albumin levels
Raw CSF and serum data were available for 628 patients: 
108 MS (75 females, 33 males); 92 OIND (42 females, 50 
males); 94 NIND (50 females, 44 males); 334 UNK (236 
females, 98 males). As reported in Fig. 2, serum albumin 
concentrations were negatively correlated to age in all 
patients analysed as a whole (r = − 0.3497, p < 0.0001) and 
in female and male subgroups (r = − 0.3155, p < 0.0001 
and r = − 0.4396, p < 0.0001, respectively). CSF albu-
min levels were positively correlated to age in the entire 
population (r = 0.2225, p < 0.0001) and in the female sub-
group (r = 0.229, p < 0.0001). QAlb was positively corre-
lated to age in all patients analysed as a whole (r = 0.3166, 
p < 0.0001) and grouped by sex (r = 0.3124, p < 0.0001 in 
females; r = 0.1561, p = 0.0191 in males).
Correlations between QAlb and disability in multiple 
sclerosis patients
At the time of sample collection disease severity was 
scored using Kurtzke’s Expanded Disability Status Scale 
(EDSS) [22] in 286 MS patients (199 women and 87 men). 
EDSS values were similar (Mann–Whitney: p = 0.4343) 
between women (median and interquartile range (IQR): 
2.5, 1.5–3.5) and men (median and IQR: 3.0, 1.5–3.5). 
QAlb values were positively correlated to the EDSS in 
the MS group analysed as a whole (Spearman: r = 0.1535, 
95% CI 0.03481 to 0.2680; p = 0.0093) and in the females 
subgroup (Spearman: r = 0.1789, 95% CI 0.03666 to 
0.3140; p = 0.0115), data not shown.
Table 2 Frequency of  diagnoses of  blood–CSF barrier (B–
CSF–B) dysfunction in  the  study population by  sex, age 
and specific disease status
B-CSF-B dysfunction was defined using the cerebrospinal fluid (CSF)/serum 
albumin quotient (QAlb) with the following upper reference limits: 6.5 for 
patients aged 16–40 years, 8.0 for patients aged 41–60 years and 9.0 for patients 
over 60 years. Chi square test was used for all comparisons
ALL patient groups analysed as a whole, MS multiple sclerosis, NIND non-
inflammatory neurological diseases, OIND other inflammatory neurological 
diseases, UNK unknown-neurological diagnosis
Female Male p
All: n (%) 718 (59.4) 491 (40.6)
Altered B-CSF-B: n (%) 150 (20.1) 216 (44.0) < 0.0001
 Age 16–40 years: n (%) 37 (11.8) 66 (40.8) < 0.0001
 Age 41–60 years: n (%) 60 (23.4) 78 (44.3) < 0.0001
 Age > 60 years: n (%) 53 (33.3) 72 (47.1) 0.0134
MS: n (%) 204 (68.7) 93 (31.3)
 Altered B-CSF-B: n (%) 15 (7.35) 23 (24.7) < 0.0001
OIND: n (%) 132 (47.0) 149 (53.0)
 Altered B-CSF-B: n (%) 60 (45.5) 89 (59.7) 0.0167
NIND: n (%) 146 (49.2) 151 (50.8)
 Altered B-CSF-B: n (%) 23 (15.8) 50 (33.1) 0.0005
UNK: n (%) 236 (70.7) 98 (29.3)
 Altered B–CSF–B: n (%) 52 (22.0) 54 (55.1) < 0.0001
Table 3 Albumin quotient (QAlb) distribution in the study 
population by sex, age and specific disease status
Mann–Whitney u-test was used for all comparisons
ALL patient groups analysed as a whole, MS multiple sclerosis, NIND non-
inflammatory neurological diseases, OIND other inflammatory neurological 
diseases, UNK unknown-neurological diagnosis
Females Males p
ALL, n (%) 718 (59.4) 491 (40.6)
QAlb: median (IQR) 4.87 (3.69–6.88) 7.18 (4.91–11.30) < 0.0001
 Age 16–40 years: 
median (IQR)
4.19 (3.28–5.41) 5.74 (4.40–9.20) < 0.0001
 Age 41–60 years: 
median (IQR)
5.03 (3.88–7.83) 7.33 (4.87–11.26) < 0.0001
 Age > 60 years: median 
(IQR)
6.52 (4.93–10.96) 8.87 (5.82–15.43) 0.0008
MS, n (%) 204 (68.7) 93 (31.3)
 QAlb: median (IQR) 4.10 (3.27–5.36) 5.22 (4.15–7.61) < 0.0001
OIND, n (%) 132 (47.0) 149 (53.0)
 QAlb: median (IQR) 6.68 (4.54–13.1) 9.22 (5.65–15.00) 0.0172
NIND, n (%) 146 (49.2) 151 (50.8)
 QAlb: median (IQR) 5.09 (3.87–6.58) 6.34 (4.64–9.42) < 0.0001
UNK, n (%) 236 (70.7) 98 (29.3)
 QAlb: median (IQR) 4.89 (3.70–7.38) 8.48 (6.2–12.4) < 0.0001
Page 5 of 9Castellazzi et al. Fluids Barriers CNS           (2020) 17:14 
Table 4 Prevalence of sex across albumin quotient (QAlb) quartiles
Chi square test was used for all comparisons
ALL patient groups analysed as a whole, MS multiple sclerosis, NIND non-inflammatory neurological diseases, OIND other inflammatory neurological diseases, UNK 
unknown-neurological diagnosis
Q1 (QAlb < 4.06) Q2 (4.06 < QAlb < 5.57) Q3 (5.58 < QAlb < 8.97) Q4 (QAlb > 8.98) p
All (n = 1209)
 Female: n (%) 244 (81.3) 194 (63.6) 158 (52.3) 122 (40.4) <0.0001
 Male: n (%) 56 (18.7) 11 (36.4) 144 (47.7) 180 (59.6)
MS (n = 297)
 Female: n (%) 101 (82.8) 58 (67.4) 35 (53.8) 10 (41.7) <0.0001
 Male: n (%) 21 (17.2) 28 (32.6) 30 (46.2) 14 (58.3)
OIND (n = 281)
 Female: n (%) 23 (67.7) 25 (51.0) 31 (47.7) 53 (39.8) 0.0309
 Male: n (%) 11 (32.4) 24 (49.0) 34 (52.3) 80 (60.2)
NIND (n = 297)
 Female: n (%) 43 (71.7) 47 (50.0) 37 (44.6) 19 (31.7) 0.0002
 Male: n (%) 17 (28.3) 47 (50.0) 46 (55.4) 41 (68.3)
UNK (n = 334)
 Female: n (%) 77 (91.7) 64 (84.2) 55 (61.8) 40 (47.1) <0.0001
 Male: n (%) 7 (8.3) 12 (15.8) 34 (38.2) 45 (52.9)
Age 16–40 (n = 465)
 Female: n (%) 139 (84.2) 92(64.3) 58 (57.4) 14 (25.0) <0.0001
 Male: n (%) 26 (15.8) 51 (35.7) 43 (42.6) 42 (75.0)
Age 41–60 (n = 435)
 Female: n (%) 83 (78.3) 63 (64.9) 57 (51.4) 53 (43.8) <0.0001
 Male: n (%) 23 (21.7) 34 (35.1) 54 (48.6) 68 (56.2)
Age > 60 (n = 309)
 Female: n (%) 22 (75.9) 39 (60.0) 43 (47.8) 55 (44.0) 0.0071
 Male: n (%) 7 (24.1) 26 (40.0) 47 (52.2) 70 (56.0)
Fig. 1 Linear regression analysis of albumin quotient (QAlb) and age in male and female patients. aQAlb and age were positively correlated in male 
(Spearman, p < 0.0001) and female (Spearman, p < 0.0001) patients. bThe slopes of the two regression lines were not significantly different (F test, 
p = 0.7149). cThe difference between the elevations was significant (F test, p < 0.0001)
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Discussion
In our study we have shown that both older age and 
male sex are independently associated with higher 
QAlb in a large population of neurological patients. 
Because QAlb reflects B-CSF-B dysfunction [4, 5], this 
condition is therefore more frequently assigned to men 
than to women, irrespective of age and specific disease 
status.
Our findings are in line with those from a study by 
Parrado-Fernández et al. which was recently conducted 
in a population of over 20,000 patients with unspeci-
fied diseases as well as in control subjects [17]. They 
observed significantly higher QAlb in men than in 
women and irrespective of age, but the implications of 
such a sex discrepancy on B-CSF-B dysfunction were 
not discussed (e.g., in terms of percentage of patients 
positive for abnormal QAlb value).
Since it was introduced in 1977 [8], QAlb has been 
considered the best marker of B-CSF-B permeability 
dysfunction, the “B-CSF-B dysfunction”, by different 
expert panels [4, 9, 23, 24].
QAlb is reported to be normal or only rarely 
increased in MS [9]. In the present work, we observed 
that nearly 25% of male, compared to less than 10% 
of female, MS patients reported levels of QAlb which 
may indicate B-CSF-B dysfunction. Moreover, here we 
report that in MS patients, and particularly in females, 
an increase in disease severity seems to be associated 
to an altered B-CSF-B permeability. Now, we can only 
speculate that this increase could be the consequence 
of a modified posture and/or a reduced physical activity 
due to the disease progression [25, 26].
Elevated QAlb values have been reported above all in 
OIND and also, although less frequently, in NIND and in 
patients without neurological disorders [10, 27]. Accord-
ingly, in our study population, for almost 60% of OIND 
and 33% of NIND male patients, an altered B-CSF-B 
could ultimately be reported, regardless of the inflamma-
tory nature of the disease.
As has also been observed in other studies [28], in our 
population of neurological patients, QAlb increased with 
age while serum albumin levels decreased regardless of 
sex, whereas CSF levels remained almost stable in men 
and increased significantly in women. These observations 
confirm that B-CSF-B permeability to albumin changes 
in relation to age in the two sexes, albeit in a different 
way.
Sex-specific differences in QAlb values may be second-
ary to a number of mechanisms. The female hormone, 
17β-estradiol [29], may drive a different expression of the 
enzymes involved in the BBB breakdown [30, 31], ulti-
mately leading to a protective role on BBB [32]. Interest-
ingly, because QAlb sex-specific values do not change in 
puberty or menopause, the role of a genetic predisposi-
tion linked to sex chromosomes together with that of 
hormones themselves should be considered [17, 33].
Also, a difference in the CSF flow rate between sexes 
may explain the sex-specific differences in QAlb. For 
decades QAlb has been regarded as increasing with age 
[9, 13, 34], in relation to the reduced speed of CSF in the 
elderly [35], and an increase in CSF albumin concentra-
tion has also been associated to the reduced CSF turno-
ver occuring in the aging process [16, 36].
Other factors such as the use of oral contraception in 
females [37] or posture and physical activity [25] have 
been reported to influence the albumin CSF/serum ratio, 
however, to date a widely recognized agreement on the 
actual role of these potentially confounding factors is still 
lacking.
From another perspective, the different distribution 
of QAlb defined B-CSF-B dysfunction by sex indeed 
opens up a discussion on the relevant potential implica-
tions for clinical practice. If this difference is genetically 
determined [17, 33], we believe that QAlb threshold val-
ues should be normalized by sex and age in order not to 
overestimate B-CSF-B alteration in men, or, on the con-
trary, underestimate it in women. In the present work, 
QAlb values appear to be 2.2 units higher in men than 
in women irrespective of age and neurological pathology. 
This coefficient might be considered for future establish-
ment of QAlb thresholds.
Even in the absence of B-CSF-B alteration, however, 
the sex-specific difference of QAlb may still reflect 
Table 5 Predictors of albumin quotient (QAlb)
log (QAlb) in multivariate regression analysis
ALL patient groups analysed as a whole, MS multiple sclerosis, NIND non-
inflammatory neurological diseases, OIND other inflammatory neurological 
diseases, UNK unknown-neurological diagnosis
B (SE) p
ALL (n = 1209)
 Age 0.31 (0.00) < 0.001
 Sex, M 0.25 (0.02) < 0.001
MS (n = 297)
 Age 0.24 (0.01) < 0.001
 Sex, M 0.29 (0.02) < 0.001
OID (n = 281)
 Age 0.22 (0.00) < 0.001
 Sex, M 0.12 (0.04) < 0.001
NID (n = 297)
 Age 0.24 (0.00) < 0.001
 Sex, M 0.28 (0.03) < 0.001
UNK (n = 334)
 Age 0.29 (0.00) < 0.001
 Sex, M 0.32 (0.03) < 0.001
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corresponding differences in B-CSF-B permeability and/
or CSF flow/turnover also in normal subjects. In this per-
spective, differential drug delivery to the CNS should be 
hypothesized, and sex-specific pharmacological strate-
gies may be required to ensure the most effective drug 
concentration crossing the BBB.
Fig. 2 Correlations between age and albumin levels in cerebrospinal fluid (CSF) and serum. Serum albumin levels decreased with age in all patients 
analysed as a whole (Spearman: p < 0.0001) and grouped by sex (Spearman: p < 0.0001 for woman and p < 0.0001 for men). CSF albumin levels 
increased with age in the entire population (Spearman: p < 0.0001) and in the female subgroup (Spearman: p < 0.0001). The CSF/serum albumin 
ratio (QAlb) increased with age in all patients analysed as a whole (Spearman: p < 0.0001) and grouped by sex (Spearman: p < 0.0001 in women and 
p = 0.0191 in men). CI confidence interval
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Finally, it is worth reporting that it has recently been 
shown that glial cells in the CNS can produce albumin [7, 
38–40], but how much this contributes to the total CSF 
albumin concentration is still being debated. QAlb, there-
fore, still remains the only validated laboratory tool for 
assessing B-CSF-B permeability.
Our study has some limitations. The analysis did not 
include a healthy donor population so a comparison 
between neurological patients and a healthy popula-
tion could not be made. Thus, it is possible that the 
male/female and age differences might be due to altered 
responses to disease. However, we did include groups 
with different neurological pathologies, i.e., MS, OIND 
and NIND, which ultimately showed similar QAlb distri-
bution, and were in line with existing evidence on healthy 
subjects reported elsewhere [17]. Furthermore, we 
acknowledge that a specific neurological diagnosis was 
not available for ca 25% of the study population. How-
ever, these were patients who had been admitted to the 
Unit of Neurology and who could have been assigned to 
any of the three groups, across which no differential pat-
tern of QAlb distribution by sex and age was observed.
Conclusions
Our study reveals that, regardless of age, male neurologi-
cal patients show B-CSF-B dysfunction more frequently 
than females, based on QAlb values. This evidence opens 
up discussion on whether the current QAlb thresh-
old needs to be revised e.g., by introducing a corrective 
factor, in consideration of sex-genetically background 
differences, or whether B-CSF-B permeability truly dif-
fers between sexes, making men more prone to B-CSF-
B dysfunction than women. In any case, future studies 
are required to evaluate whether the gap of 2.2 units we 
found between male and female neurological patients 
might be applied as a sex-related corrective factor to the 
thresholds for the evaluation of B-CSF-B permeability 
through the QAlb.
In an era of cost-effective personalised medicine, these 
considerations could have practical implications on sex-
specific prognosis of neurological disorders as well as on 
the choice of the best strategy for drug delivery into the 
CNS.
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